

&lt;400&gt; 227

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr  
1 5 10

&lt;210&gt; 228

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

&lt;220&gt;

&lt;223&gt; At position 1, optionally acetylated at N-terminus

&lt;220&gt;

&lt;223&gt; At position 10, Xaa=azetidine

&lt;400&gt; 228

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr  
1 5 10

&lt;210&gt; 229

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

&lt;220&gt;

&lt;223&gt; At position 6, products="MeGly"

&lt;220&gt;

&lt;223&gt; At position 10, Xaa=azetidine

&lt;400&gt; 229

Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr  
1 5 10

<210> 230  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>  
<223> At position 6, Xaa=MeGly

<220>  
<223> At position 10, Xaa=azetidine

<400> 230  
Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr  
1 5 10

<210> 231  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<400> 231  
Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Pro Tyr  
1 5 10

<210> 232  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<400> 232  
Phe Glu Trp Thr Pro Gly Trp Trp Gln Pro Tyr

1

5

10

&lt;210&gt; 233

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

&lt;400&gt; 233

Phe Glu Trp Thr Pro Asn Tyr Trp Gln Pro Tyr  
1 5 10

&lt;210&gt; 234

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

&lt;220&gt;

&lt;223&gt; At position 5, Xaa=pipecolic acid

&lt;220&gt;

&lt;223&gt; At position 10, Xaa=azetidine

&lt;400&gt; 234

Phe Glu Trp Thr Xaa Val Tyr Trp Gln Xaa Tyr  
1 5 10

&lt;210&gt; 235

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 5, Xaa=pipecolic acid

<220>

<223> At position 10, Xaa=azetidine

<400> 235

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr

1

5

10

<210> 236

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 6, Xaa=Aib

<220>

<223> At position 10, Xaa=azetidine

<400> 236

Phe Glu Trp Thr Pro Xaa Tyr Trp Gln Xaa Tyr

1

5

10

<210> 237

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 5, Xaa=MeGly

<220>

<223> At position 10, Xaa=azetidine

<400> 237

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr  
1 5 10

<210> 238

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 11, amino group added at C-terminus

<400> 238

Phe Glu Trp Thr Pro Gly Tyr Trp Gln Pro Tyr  
1 5 10

<210> 239

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 11, amino group added at C-terminus

<400> 239

Phe Glu Trp Thr Pro Gly Tyr Trp Gln His Tyr  
1 5 10

<210> 240

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11 amino group added at C-terminus

<400> 240

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr  
1 5 10

<210> 241

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 1, optionally acetylated at  
N-terminus

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11 amino group added at C-terminus

<400> 241

Phe Glu Trp Thr Pro Gly Trp Tyr Gln Xaa Tyr  
1 5 10

<210> 242

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST

## PEPTIDE

&lt;220&gt;

&lt;223&gt; At position 8, Xaa is a phyosphotyrosyl residue

&lt;220&gt;

&lt;223&gt; At position 10, Xaa is an azetidine residue

&lt;220&gt;

&lt;223&gt; At position 11, amino group added at C-terminus

&lt;400&gt; 242

Phe Glu Trp Thr Pro Gly Trp Xaa Gln Xaa Tyr

1

5

10

&lt;210&gt; 243

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

&lt;220&gt;

&lt;223&gt; At position 10, Xaa is an azetidine residue

&lt;220&gt;

&lt;223&gt; At position 11 amino group added at C-terminus

&lt;400&gt; 243

Phe Ala Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr

1

5

10

&lt;210&gt; 244

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

&lt;220&gt;

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11 amino group added at C-terminus

<400> 244

Phe Glu Trp Ala Pro Gly Tyr Trp Gln Xaa Tyr

1

5

10

<210> 245

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11 amino group added at C-terminus

<400> 245

Phe Glu Trp Val Pro Gly Tyr Trp Gln Xaa Tyr

1

5

10

<210> 246

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11 amino group added at C-terminus

<400> 246



Phe Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr  
1 5 10

<210> 247

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 1 acetylated at N-terminus

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11 amino group added at C-terminus

<400> 247

Xaa Glu Trp Thr Pro Gly Tyr Trp Gln Xaa Tyr  
1 5 10

<210> 248

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 6, D amino acid residue

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11 amino group added at C-terminus

<400> 248

Phe Glu Trp Thr Pro Ala Trp Tyr Gln Xaa Tyr  
1 5 10

<210> 249

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 6, Xaa is a sarcosine residue

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11 amino group added at C-terminus

<400> 249

Phe Glu Trp Thr Pro Xaa Trp Tyr Gln Xaa Tyr  
1 5 10

<210> 250

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 11 amino group added at C-terminus

<400> 250

Phe Glu Trp Thr Pro Gly Tyr Tyr Gln Pro Tyr  
1 5 10

<210> 251

<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 11 amino group added at C-terminus

<400> 251

Phe	Glu	Trp	Thr	Pro	Gly	Trp	Trp	Gln	Pro	Tyr
1				5				10		

<210> 252

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 11 amino group added at C-terminus

<400> 252

Phe	Glu	Trp	Thr	Pro	Asn	Tyr	Trp	Gln	Pro	Tyr
1				5				10		

<210> 253

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 6, D amino acid residue

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11, amino group added at C-terminus

<400> 253

Phe Glu Trp Thr Pro Val Tyr Trp Gln Xaa Tyr  
1 5 10

<210> 254

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 5, Xaa is a pipecolic acid residue

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11, amino group added at C-terminus

<400> 254

Phe Glu Trp Thr Xaa Gly Tyr Trp Gln Xaa Tyr  
1 5 10

<210> 255

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 6, Xaa=pipecolic acid

<220>

<223> At position 10, Xaa=azetidine

<400> 255

Phe	Glu	Trp	Thr	Pro	Xaa	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 256

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 5, Xaa=MeGly

<220>

<223> At position 10, Xaa=azetidine

<400> 256

Phe	Glu	Trp	Thr	Xaa	Gly	Tyr	Trp	Gln	Xaa	Tyr
1				5					10	

<210> 257

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INTEGRIN  
BINDING PEPTIDE

<400> 257

Phe	Glu	Trp	Thr	Pro	Gly	Tyr	Trp	Gln	Pro	Tyr	Ala	Leu	Pro	Leu
1				5					10				15	

<210> 258

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 1, Xaa is a 1-naphthylalanine residue

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11, amino group added at C-terminus

<400> 258

Xaa Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr  
1 5 10

<210> 259

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<220>

<223> At position 10, Xaa is a azetidine residue

<220>

<223> At position 11, amino group added at C-terminus

<400> 259

Tyr Glu Trp Thr Pro Gly Tyr Tyr Gln Xaa Tyr  
1 5 10

<210> 260

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST

## PEPTIDE

&lt;220&gt;

&lt;223&gt; At position 10, Xaa is an azetidine residue

&lt;220&gt;

&lt;223&gt; At position 11, amino group added at C-terminus

&lt;400&gt; 260

Phe Glu Trp Val Pro Gly Tyr Tyr Gln Xaa Tyr  
1 5 10

&lt;210&gt; 261

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

&lt;220&gt;

&lt;223&gt; At position 6, D amino acid residue

&lt;220&gt;

&lt;223&gt; At position 10, Xaa is an azetidine residue

&lt;220&gt;

&lt;223&gt; At position 11, amino group added at C-terminus

&lt;400&gt; 261

Phe Glu Trp Thr Pro Ser Tyr Tyr Gln Xaa Tyr  
1 5 10

&lt;210&gt; 262

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

&lt;220&gt;

<223> At position 6, D amino acid residue

<220>

<223> At position 10, Xaa is an azetidine residue

<220>

<223> At position 11, amino group added at C-terminus

<400> 262

Phe	Glu	Trp	Thr	Pro	Asn	Tyr	Tyr	Gln	Xaa	Tyr
1				5					10	

<210> 263

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<400> 263

Thr	Lys	Pro	Arg
1			

<210> 264

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<400> 264

Arg	Lys	Ser	Ser	Lys
1				5

<210> 265

<211> 5

<212> PRT

<213> Artificial Sequence



<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<400> 265

Arg Lys Gln Asp Lys  
1 5

<210> 266

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<400> 266

Asn Arg Lys Gln Asp Lys  
1 5

<210> 267

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<400> 267

Arg Lys Gln Asp Lys Arg  
1 5

<210> 268

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:IL-1 ANTAGONIST

## PEPTIDE

&lt;400&gt; 268

Glu Asn Arg Lys Gln Asp Lys Arg Phe

1

5

&lt;210&gt; 269

&lt;211&gt; 6

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

&lt;400&gt; 269

Val Thr Lys Phe Tyr Phe

1

5

&lt;210&gt; 270

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

&lt;400&gt; 270

Val Thr Lys Phe Tyr

1

5

&lt;210&gt; 271

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

&lt;400&gt; 271

Val Thr Asp Phe Tyr  
1 5

<210> 272  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:IL-1 ANTAGONIST  
PEPTIDE

<400> 272  
Ser Gly Ser Gly Val Leu Lys Arg Pro Leu Pro Ile Leu Pro Val Thr  
1 5 10 15

Arg

<210> 273  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:MCA/MCP  
PROTEASE INHIBITOR PEPTIDE

<400> 273  
Arg Trp Leu Ser Ser Arg Pro Leu Pro Pro Leu Pro Leu Pro Pro Arg  
1 5 10 15

Thr

<210> 274  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:MCA/MCPPROTEASE

## INHIBITOR PEPTIDE

&lt;400&gt; 274

Gly Ser Gly Ser Tyr Asp Thr Leu Ala Leu Pro Ser Leu Pro Leu His  
1 5 10 15

Pro Met Ser Ser  
20

&lt;210&gt; 275

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:MCA/MCP  
PROTEASE INHIBITOR PEPTIDE

&lt;400&gt; 275

Gly Ser Gly Ser Tyr Asp Thr Arg Ala Leu Pro Ser Leu Pro Leu His  
1 5 10 15

Pro Met Ser Ser  
20

&lt;210&gt; 276

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:MCA/MCP  
PROTEASE INHIBITOR PEPTIDE

&lt;400&gt; 276

Gly Ser Gly Ser Ser Gly Val Thr Met Tyr Pro Lys Leu Pro Pro His  
1 5 10 15

Trp Ser Met Ala  
20

&lt;210&gt; 277

<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:MCA/MCP  
PROTEASE INHIBITOR PEPTIDE

<400> 277  
Gly Ser Gly Ser Ser Gly Val Arg Met Tyr Pro Lys Leu Pro Pro His  
1 5 10 15

Trp Ser Met Ala  
20

<210> 278  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:MCA/MCP  
PROTEASE INHIBITOR PEPTIDE

<400> 278  
Gly Ser Gly Ser Ser Ser Met Arg Met Val Pro Thr Ile Pro Gly Ser  
1 5 10 15

Ala Lys His Gly  
20

<210> 279  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:ANTI-HBV  
PEPTIDE

<400> 279  
Leu Leu Gly Arg Met Lys  
1 5

<210> 280

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ANTI-HBV  
PEPTIDE

<400> 280

Ala Leu Leu Gly Arg Met Lys Gly

1

5

<210> 281

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:ANTI-HBV  
PEPTIDE

<400> 281

Leu Asp Pro Ala Phe Arg

1

5

<210> 282

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 282

Arg Pro Leu Pro Pro Leu Pro

1

5

<210> 283

<211> 7

<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 283

Arg Glu Leu Pro Pro Leu Pro  
1 5

<210> 284

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:MSH3 ANTAGONIST

<400> 284

Ser Pro Leu Pro Pro Leu Pro  
1 5

<210> 285

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 285

Gly Pro Leu Pro Pro Leu Pro  
1 5

<210> 286

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

&lt;400&gt; 286

Arg Pro Leu Pro Ile Pro Pro

1

5

&lt;210&gt; 287

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:MAST CELL  
ANTAGONISTS/MAST CELL PROTEASE INHIBITOR

&lt;400&gt; 287

Arg Pro Leu Pro Ile Pro Pro

1

5

&lt;210&gt; 288

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:SH3 ANTAGONIST

&lt;400&gt; 288

Arg Arg Leu Pro Pro Thr Pro

1

5

&lt;210&gt; 289

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:SH3 ANTAGONIST

&lt;400&gt; 289

Arg Gln Leu Pro Pro Thr Pro

1

5



<210> 290  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 290  
Arg Pro Leu Pro Ser Arg Pro  
1 5

<210> 291  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 291  
Arg Pro Leu Pro Thr Arg Pro  
1 5

<210> 292  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 292  
Ser Arg Leu Pro Pro Leu Pro  
1 5

<210> 293  
<211> 7  
<212> PRT  
<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:SH3 ANTAGONIST

&lt;400&gt; 293

Arg Ala Leu Pro Ser Pro Pro

1

5

&lt;210&gt; 294

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:SH3 ANTAGONIST

&lt;400&gt; 294

Arg Arg Leu Pro Arg Thr Pro

1

5

&lt;210&gt; 295

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:SH3 ANTAGONIST

&lt;400&gt; 295

Arg Pro Val Pro Pro Ile Thr

1

5

&lt;210&gt; 296

&lt;211&gt; 7

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:SH3 ANTAGONIST

&lt;400&gt; 296...

Ile Leu Ala Pro Pro Val Pro

1

5

<210> 297  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 297  
Arg Pro Leu Pro Met Leu Pro  
1 5

<210> 298  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 298  
Arg Pro Leu Pro Ile Leu Pro  
1 5

<210> 299  
<211> 7  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 299  
Arg Pro Leu Pro Ser Leu Pro  
1 5

<210> 300  
<211> 7  
<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 300

Arg Pro Leu Pro Ser Leu Pro

1

5

<210> 301

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 301

Arg Pro Leu Pro Met Ile Pro

1

5

<210> 302

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 302

Arg Pro Leu Pro Leu Ile Pro

1

5

<210> 303

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 303

Arg Pro Leu Pro Pro Thr Pro  
1 5

<210> 304

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 304

Arg Ser Leu Pro Pro Leu Pro  
1 5

<210> 305

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 305

Arg Pro Gln Pro Pro Pro Pro  
1 5

<210> 306

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 306

Arg Gln Leu Pro Ile Pro Pro  
1 5

<210> 307

<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 307  
Xaa Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Pro  
1 5 10

<210> 308  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 308  
Xaa Xaa Xaa Arg Pro Leu Pro Pro Ile Pro Xaa Xaa  
1 5 10

<210> 309  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 309  
Xaa Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Xaa  
1 5 10

<210> 310  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:SH3 ANTAGONIST

&lt;400&gt; 310

Arg Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Xaa Pro  
1 5 10

&lt;210&gt; 311

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:SH3 ANTAGONIST

&lt;400&gt; 311

Arg Xaa Xaa Arg Pro Leu Pro Pro Leu Pro Pro Pro  
1 5 10

&lt;210&gt; 312

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:SH3 ANTAGONIST

&lt;400&gt; 312

Pro Pro Pro Tyr Pro Pro Pro Pro Ile Pro Xaa Xaa  
1 5 10

&lt;210&gt; 313

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:SH3 ANTAGONIST

&lt;400&gt; 313

Pro Pro Pro Tyr Pro Pro Pro Pro Val Pro Xaa Xaa  
1 5 10

<210> 314

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 314

Leu Xaa Xaa Arg Pro Leu Pro Xaa Xaa Pro  
1 5 10

<210> 315

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>

<223> At position 1, Xaa is an aliphatic amino acid  
residue

<400> 315

Xaa Xaa Xaa Arg Pro Leu Pro Xaa Leu Pro  
1 5 10

<210> 316

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>

<223> At position 4, Xaa is an aromatic amino acid  
residue

<220>

<223> At position 9, Xaa is an aliphatic amino acid  
residue



<400> 316

Pro Pro Xaa Xaa Tyr Pro Pro Pro Xaa Pro  
1 5 10

<210> 317

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>

<223> At position 1, Xaa is a basic amino acid residue

<220>

<223> At position 4, Xaa is an aliphatic amino acid  
residue

<400> 317

Xaa Pro Pro Xaa Pro Xaa Lys Pro Xaa Trp Leu  
1 5 10

<210> 318

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>

<223> At position 4, Xaa is an aliphatic amino acid  
residue

<220>

<223> At position 6, Xaa is an aliphatic amino acid  
residue

<220>

<223> At position 8, Xaa is a basic amino acid residue

<400> 318

Arg Pro Xaa Xaa Pro Xaa Arg Xaa Ser Xaa Pro  
1 5 10

<210> 319

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 319

Pro Pro Val Pro Pro Arg Pro Xaa Xaa Thr Leu  
1 5 10

<210> 320

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>

<223> At positions 1, 3 and 6, Xaa is an aliphatic  
amino acid residue

<400> 320

Xaa Pro Xaa Leu Pro Xaa Lys  
1 5

<210> 321

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<220>

<223> At position 1, Xaa is a basic amino acid residue

<220>

<223> At position 2, Xaa is an aromatic amino acid residue

<400> 321

Xaa Xaa Asp Xaa Pro Leu Pro Xaa Leu Pro  
1 5 10

<210> 322

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:INHIBITOR OF PLATELET AGGREGATION

<400> 322

Cys Xaa Xaa Arg Gly Asp Cys  
1 5

<210> 323

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SRC ANTAGONIST

<400> 323

Arg Pro Leu Pro Pro Leu Pro  
1 5

<210> 324

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SRC ANTAGONIST

<400> 324

Pro Pro Val Pro Pro Arg  
1 5

<210> 325  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:ANTI-CANCER  
PEPTIDE

<400> 325  
Xaa Phe Xaa Asp Xaa Trp Xaa Xaa Leu Xaa Xaa  
1 5 10

<210> 326  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:p16-MIMETIC  
PEPTIDE

<400> 326  
Lys Ala Cys Arg Arg Leu Phe Gly Pro Val Asp Ser Glu Gln Leu Ser  
1 5 10 15

Arg Asp Cys Asp  
20

<210> 327  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:p16-MIMETIC  
PEPTIDE

<400> 327

Arg Glu Arg Trp Asn Phe Asp Phe Val Thr Glu Thr Pro Leu Glu Gly  
1 5 10 15

Asp Phe Ala Trp  
20

<210> 328

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:p16-MIMETIC  
PEPTIDE

<400> 328

Lys Arg Arg Gln Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg  
1 5 10 15

Leu Ile Phe Ser  
20

<210> 329

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:SH3 ANTAGONIST

<400> 329

Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser  
1 5 10 15

Lys Arg Lys Pro  
20

<210> 330

<211> 5

<212> PRT

<213> Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:p16-MIMETIC  
PEPTIDE

&lt;400&gt; 330

Arg Arg Leu Ile Phe  
1 5

&lt;210&gt; 331

&lt;211&gt; 36

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:p16-MIMETIC  
PEPTIDE

&lt;400&gt; 331

Lys Arg Arg Gln Thr Ser Ala Thr Asp Phe Tyr His Ser Lys Arg Arg  
1 5 10 15Leu Ile Phe Ser Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met  
20 25 30Lys Trp Lys Lys  
35

&lt;210&gt; 332

&lt;211&gt; 24

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:p16-MIMETIC  
PEPTIDE

&lt;400&gt; 332

Lys Arg Arg Leu Ile Phe Ser Lys Arg Gln Ile Lys Ile Trp Phe Gln  
1 5 10 15Asn Arg Arg Met Lys Trp Lys Lys  
20

<210> 333  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:POLYGLYCINE  
LINKER

<400> 333  
Gly Gly Gly Lys Gly Gly Gly Gly  
1 5

<210> 334  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:POLYGLYCINE  
LINKER

<400> 334  
Gly Gly Gly Asn Gly Ser Gly Gly  
1 5

<210> 335  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:POLYGLYCINE  
LINKER

<400> 335  
Gly Gly Gly Cys Gly Gly Gly Gly  
1 5

<210> 336  
<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:FC PCR PRIMER

<400> 336

Gly Pro Asn Gly Gly  
1 5

<210> 337

<211> 42

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 337

Phe Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu  
1 5 10 15

Ala Ala Arg Ala Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro  
20 25 30

Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala  
35 40

<210> 338

<211> 42

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 338

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu  
20 25 30

Ala Ala Arg Ala Gly Gly Gly Gly Gly Phe



35

40

<210> 339  
 <211> 50  
 <212> PRT  
 <213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:TPO-MIMETIC

&lt;400&gt; 339

Phe Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe Gly Pro  
 1 5 10 15

Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly  
 20 25 30

Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys Pro Gln  
 35 40 45

Gly Gly  
 50

<210> 340  
 <211> 50  
 <212> PRT  
 <213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:EPO-MIMETIC

&lt;400&gt; 340

Gly Gly Thr Tyr Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys  
 1 5 10 15

Pro Gln Gly Gly Gly Gly Gly Gly Gly Gly Thr Tyr Ser Cys His Phe  
 20 25 30

Gly Pro Leu Thr Trp Val Cys Lys Pro Gln Gly Gly Gly Gly Gly Gly  
 35 40 45

Gly Phe  
 50

<210> 341

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC  
PEPTIDES

<400> 341

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Ile Glu  
1 5 10 15

Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala  
20 25

<210> 342

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 342

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Ile  
1 5 10 15

Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala  
20 25

<210> 343

<211> 30

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 343

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala  
20 25 30

<210> 344

<211> 31

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 344

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala  
20 25 30

<210> 345

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC

<400> 345

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala  
20 25 30

<210> 346

<211> 33

<212> PRT

<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:TPO-MIMETIC

&lt;400&gt; 346

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg  
20 25 30

Ala

&lt;210&gt; 347

&lt;211&gt; 34

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:TPO-MIMETIC

&lt;400&gt; 347

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala  
20 25 30

Arg Ala

&lt;210&gt; 348

&lt;211&gt; 35

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:TPO-MIMETIC

&lt;400&gt; 348

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala

20

25

30

Ala Arg Ala  
35

&lt;210&gt; 349

&lt;211&gt; 36

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:TPO-MIMETIC

&lt;400&gt; 349

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu  
20 25 30

Ala Ala Arg Ala  
35

&lt;210&gt; 350

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence:TPO-MIMETIC  
PEPTIDES

&lt;400&gt; 350

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp  
20 25 30

Leu Ala Ala Arg Ala  
35

<210> 351  
<211> 38  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:TPO-MIMETIC  
PEPTIDES

<400> 351  
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15  
Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln  
20 25 30  
Trp Leu Ala Ala Arg Ala  
35

<210> 352  
<211> 42  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:TPO-MIMETIC  
PEPTIDES

<400> 352  
Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15  
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro  
20 25 30  
Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala  
35 40

<210> 353  
<211> 32  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC  
PEPTIDES

<400> 353

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Pro  
1 5 10 15

Asn Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala  
20 25 30

<210> 354

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC  
PEPTIDES

<400> 354

Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu  
20 25 30

Ala Ala Arg Ala  
35

<210> 355

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC  
PEPTIDES

<400> 355

Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Cys Leu  
20 25 30

Ala Ala Arg Ala  
35

<210> 356

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC  
PEPTIDES

<400> 356

Ile Glu Gly Pro Thr Leu Arg Gln Ala Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Gly Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Ala Leu  
20 25 30

Ala Ala Arg Ala  
35

<210> 357

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC  
PEPTIDES

<400> 357

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Gly Lys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu  
20 25 30

Ala Ala Arg Ala  
35



<210> 358

<211> 40

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC  
PEPTIDES

<400> 358

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Gly Lys Asx Arg Ala Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu  
20 25 30

Arg Gln Trp Leu Ala Ala Arg Ala  
35 40

<210> 359

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC  
PEPTIDES

<400> 359

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Gly Cys Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu  
20 25 30

Ala Ala Arg Ala  
35

<210> 360

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC  
PEPTIDES

<400> 360

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Gly Lys Pro Glu Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg  
20 25 30

Gln Trp Leu Ala Ala Arg Ala  
35

<210> 361

<211> 39

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC  
PEPTIDES

<400> 361

Ile Glu Gly Pro Thr Leu Arg Gln Trp Leu Ala Ala Arg Ala Gly Gly  
1 5 10 15

Gly Cys Pro Glu Gly Gly Gly Gly Gly Ile Glu Gly Pro Thr Leu Arg  
20 25 30

Gln Trp Leu Ala Ala Arg Ala  
35

<210> 362

<211> 36

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:TPO-MIMETIC  
PEPTIDES